Ji, Dongmei
Shen, Weina
Li, Ting
Wang, Huan
Bai, Jianling
Cao, Junning
Hu, Xichun
Article History
Received: 19 March 2024
Accepted: 26 April 2024
First Online: 22 July 2024
Declarations
:
: The protocol and its amendments as well as the informed consent form were reviewed and approved by the independent ethics committee of Fudan University Shanghai Cancer Center (Shanghai, China). This trial conformed to the International Conference on Harmonization Good Clinical Practice guidelines and Good Clinical Laboratory Practice. The study was reported in accordance with ICMJE and Good Publication Practice Guidelines.
: Written informed consent forms were signed by all patients prior to initiating any studyrelated activities.
: Not applicable.
: Jianling Bai received research grant from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Huan Wang was the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No potential conflicts of interest are reported from other authors.